http://54.88.27.110/press-release-07-08-2021/http://54.88.27.110/press-release-07-21-2021/http://54.88.27.110/press-release-08-05-2021/http://54.88.27.110/press-release-11-19-2021/http://54.88.27.110/press-release-12-22-2021/http://54.88.27.110/press-release-01-08-22/http://54.88.27.110/press-release-03-17-22/http://54.88.27.110/press-release-03-31-22/http://54.88.27.110/press-release-04-07-22/http://54.88.27.110/press-release-04-12-22/http://54.88.27.110/press-release-05-12-22/http://54.88.27.110/press-release-06-24-22/http://54.88.27.110/press-release-08-09-22/http://54.88.27.110/press-release-11-01-22/http://54.88.27.110/press-release-07-24-2019/http://54.88.27.110/ultra-long-acting-recombinant-insulin-for-the-treatment-of-diabetes-mellitus-in-dogs/http://54.88.27.110/akston-biosciences-completes-second-licensing-and-supply-agreement-with-dechra-pharmaceuticals-plc/http://54.88.27.110/akston-biosciences-strengthens-board-with-addition-of-john-t-preston/http://54.88.27.110/helmsley-charitable-trust-and-akston-biosciences-corporation-announce-partnership-to-advance-novel-technology-to-treat-type-1-diabetes/http://54.88.27.110/akston-biosciences-awarded-phase-ii-sbir-by-nih-niddk/http://54.88.27.110/akston-biosciences-completes-series-d-preferred-stock-financing/http://54.88.27.110/akston-biosciences-completes-convertible-note-financing/http://54.88.27.110/akston-biosciences-begins-buildout-of-new-gmp-biologics-manufacturing-facility/http://54.88.27.110/akston-biosciences-receives-niddk-phase-iib-grant/http://54.88.27.110/akston-biosciences-completes-licensing-and-supply-agreement-with-dechra-pharmaceuticals-plc/http://54.88.27.110/akston-biosciences-completes-series-e-preferred-stock-financing/http://54.88.27.110/akston-biosciences-awarded-niddk-phase-iib-grant/http://54.88.27.110/akston-biosciences-receives-2-5m-milestone-payment/http://54.88.27.110/tracer-to-support-akston-biosciences-phase-1-clinical-study-of-aks-452/http://54.88.27.110/akston-and-lakepharma-announce-strategic-partnership-to-manufacture-aks-452/http://54.88.27.110/akston-biosciences-completes-second-licensing-and-supply-agreement-with-dechra-pharmaceuticals-plc-2/http://54.88.27.110/akston-biosciences-launches-phase-i-ii-clinical-trial-of-second-generation-covid-19-vaccine/http://54.88.27.110/akston-biosciences-ends-vaccine-partnership-with-stelis-continues-to-advance-covid-universal-booster-eua/